Espinola Natalia, Silvestrini Constanza, Colaci Carla, Sugg Daniela, Rojas-Roque Carlos, Coelli Jesica, Augustovski Federico
Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Doctor Emilio Ravignani, 2024, Buenos Aires, Argentina.
Sugg y Asociados Consultancy, Santiago, Chile.
Pharmacoecon Open. 2024 Sep;8(5):727-738. doi: 10.1007/s41669-024-00508-4. Epub 2024 Jul 13.
The aim of this study was to perform a budget impact analysis (BIA) of introducing olaparib treatment for adult patients with metastatic castration-resistant prostate cancer in Argentina.
A BIA model was used to estimate the cost difference between the current scenario (without olaparib) and the new scenario (incorporation of olaparib) for a third-party payer over a 5-year time horizon. The budgetary impact is estimated at the national health system level and by healthcare sectors in Argentina. Input parameters were obtained from the literature and validated by local expert opinion. Direct medical costs were obtained from both the Institute for Clinical Effectiveness and Health Policy (IECS) unit cost database and public data in Argentina. The microcosting estimation was used for key variables of the analysis. All costs are reported in US dollars (US$) as for October 2022 (1 US$ = 152.59 Argentine pesos). One-way sensitivity analyses and scenario analyses were conducted to evaluate the model robustness.
The incorporation of olaparib, with a wholesale price per pack of US$3176, was associated with a weighted average of the budget impact per member per month (PMPM) of US$0.0191 for the national health system, being slightly higher than the estimated budgeted high impact threshold (US$0.0153). The PMPM budget impact for a 5-year average ranged between US$0.007 (public sector) and US$0.033 (private sector). The duration of treatment with olaparib was the most influential parameter in the budget impact results.
The introduction of olaparib for the treatment of metastatic castration-resistant prostate cancer has a high budget impact for Argentina's health system. These findings are informative to support policy decisions aimed to expand the current treatment landscape for prostate cancer.
本研究旨在对在阿根廷为成年转移性去势抵抗性前列腺癌患者引入奥拉帕利治疗进行预算影响分析（BIA）。
使用BIA模型估计第三方支付者在5年时间范围内当前情况（无奥拉帕利）和新情况（纳入奥拉帕利）之间的成本差异。在阿根廷国家卫生系统层面和医疗保健部门估计预算影响。输入参数从文献中获取并经当地专家意见验证。直接医疗成本来自临床有效性和卫生政策研究所（IECS）单位成本数据库以及阿根廷的公共数据。对分析的关键变量采用微观成本估算。所有成本均以2022年10月的美元（1美元 = 152.59阿根廷比索）报告。进行单向敏感性分析和情景分析以评估模型的稳健性。
每包批发价为3176美元的奥拉帕利的纳入，使国家卫生系统的每位成员每月预算影响加权平均值（PMPM）为0.0191美元，略高于估计的预算高影响阈值（0.0153美元）。5年平均的PMPM预算影响在0.007美元（公共部门）至0.033美元（私营部门）之间。奥拉帕利的治疗持续时间是预算影响结果中最具影响力的参数。
在阿根廷，引入奥拉帕利治疗转移性去势抵抗性前列腺癌对卫生系统的预算影响很大。这些发现有助于支持旨在扩大当前前列腺癌治疗格局的政策决策。
